Fulcrum Therapeutics, INC. (FULC) — SEC Filings

Overview

Fulcrum Therapeutics, INC. (FULC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 11, 2025: Fulcrum Therapeutics, Inc. announced on December 10, 2025, that it entered into a material definitive agreement. The company, located at 26 Landsdowne Street, Cambridge, MA, also reported other events and filed financial statements and exhibits. This filing is made pursuant to Section 13 or 15(d) of

Sentiment Summary

Across 39 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 35 neutral, 1 mixed. The dominant filing sentiment for Fulcrum Therapeutics, INC. is neutral.

Filing Type Overview

Fulcrum Therapeutics, INC. (FULC) has filed 12 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 4 SC 13G, 13 SC 13G/A with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (39)

• Fulcrum Therapeutics Enters Material Definitive Agreement — 8-K · Dec 11, 2025 Risk: medium
  Fulcrum Therapeutics, Inc. announced on December 10, 2025, that it entered into a material definitive agreement. The company, located at 26 Landsdowne Street, C
• Fulcrum Therapeutics Files 8-K — 8-K · Dec 8, 2025 Risk: low
  Fulcrum Therapeutics, Inc. filed an 8-K on December 8, 2025, reporting on various events. The filing includes information related to financial statements and ex
• Fulcrum's Losses Mount to $54.5M Amidst Zero Collaboration Revenue — 10-Q · Oct 29, 2025 Risk: high
  Fulcrum Therapeutics, Inc. reported a significant net loss of $54.5 million for the nine months ended September 30, 2025, a substantial increase from a net inco
• 8-K Filing — 8-K · Aug 28, 2025
• Fulcrum's Q2 Loss Widens Amid Soaring R&D Costs — 10-Q · Jul 29, 2025 Risk: high
  Fulcrum Therapeutics, Inc. reported a net loss of $48.2 million for the three months ended June 30, 2025, a significant increase from the $34.5 million net loss
• Fulcrum Therapeutics Files 8-K on Shareholder Vote — 8-K · Jun 27, 2025 Risk: low
  Fulcrum Therapeutics, Inc. filed an 8-K on June 27, 2025, reporting on matters submitted to a vote of security holders as of June 26, 2025. The filing does not
• Fulcrum Therapeutics Files Q1 2025 10-Q — 10-Q · May 1, 2025 Risk: medium
  Fulcrum Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company's fiscal year ends on December 31st. Key financial data points and d
• Fulcrum Therapeutics Executive Compensation Details — DEF 14A · Apr 30, 2025 Risk: low
  Fulcrum Therapeutics, Inc. filed a DEF 14A on April 30, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes
• Fulcrum Therapeutics Terminates Material Definitive Agreement — 8-K · Mar 4, 2025 Risk: medium
  Fulcrum Therapeutics, Inc. announced on February 26, 2025, the termination of a material definitive agreement. The company, headquartered in Cambridge, Massachu
• Fulcrum Therapeutics Files 2024 10-K — 10-K · Feb 25, 2025 Risk: medium
  Fulcrum Therapeutics, Inc. filed its 2024 10-K on February 25, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on pharmaceutic
• Sanofi to Acquire Fulcrum Therapeutics for $805M — 8-K · Jan 13, 2025 Risk: medium
  Fulcrum Therapeutics, Inc. announced on January 13, 2025, that it has entered into a definitive agreement to be acquired by Sanofi for $8.00 per share in cash,
• Fulcrum Therapeutics Terminates Material Agreement — 8-K · Dec 23, 2024 Risk: medium
  Fulcrum Therapeutics, Inc. announced on December 18, 2024, the termination of a material definitive agreement. The company, located at 26 Landsdowne Street, Cam
• SC 13G Filing — SC 13G · Dec 6, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Fulcrum Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 13, 2024 Risk: medium
  Fulcrum Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial position and operational activities. K
• Fulcrum Therapeutics Announces Board and Compensation Changes — 8-K · Nov 12, 2024 Risk: medium
  Fulcrum Therapeutics, Inc. announced on November 12, 2024, changes in its board of directors and executive compensation arrangements. The filing details the dep
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G Filing — SC 13G · Nov 8, 2024
• SC 13G/A Filing — SC 13G/A · Nov 4, 2024
• SC 13G Filing — SC 13G · Oct 21, 2024
• SC 13G/A Filing — SC 13G/A · Oct 7, 2024
• Fulcrum Therapeutics Files 8-K — 8-K · Sep 24, 2024 Risk: medium
  Fulcrum Therapeutics, Inc. filed an 8-K on September 24, 2024, to report on cost associated with exit or disposal activities and financial statements and exhibi
• SC 13G Filing — SC 13G · Sep 20, 2024
• SC 13G/A Filing — SC 13G/A · Sep 16, 2024
• Fulcrum Therapeutics Files 8-K — 8-K · Sep 12, 2024 Risk: low
  Fulcrum Therapeutics, Inc. filed an 8-K on September 12, 2024, reporting other events and financial statements. The filing does not contain specific details abo
• SC 13G/A Filing — SC 13G/A · Aug 23, 2024
• Fulcrum Therapeutics Sells $100M in Stock — 8-K · Aug 22, 2024 Risk: medium
  Fulcrum Therapeutics, Inc. announced on August 21, 2024, that it entered into a securities purchase agreement for the unregistered sale of approximately $100 mi
• Fulcrum Therapeutics Files Q2 2024 10-Q — 10-Q · Jul 31, 2024 Risk: medium
  Fulcrum Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business o
• Fulcrum Therapeutics Appoints New CMO, Elects Directors — 8-K · Jun 17, 2024 Risk: medium
  Fulcrum Therapeutics, Inc. announced on June 17, 2024, the appointment of Dr. S. Brooks Marshall as Chief Medical Officer and the election of Dr. Marshall and M
• Fulcrum Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: medium
  Fulcrum Therapeutics, Inc. (FULC) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Fulcrum Therapeutics, Inc. filed a 10-Q report for the period en
• Fulcrum Therapeutics Announces 2024 Annual Meeting of Stockholders on June 17 — DEF 14A · Apr 19, 2024 Risk: low
  Fulcrum Therapeutics, Inc. (FULC) filed a Proxy Statement (DEF 14A) with the SEC on April 19, 2024. Fulcrum Therapeutics will hold its 2024 Annual Meeting of St
• Fulcrum Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 27, 2024 Risk: medium
  Fulcrum Therapeutics, Inc. (FULC) filed a Annual Report (10-K) with the SEC on February 27, 2024. Fulcrum Therapeutics, Inc. filed its annual report on Form 10-
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• FMR LLC & Abigail Johnson Maintain 9.195% Stake in Fulcrum Therapeutics — SC 13G/A · Feb 9, 2024 Risk: low
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Fulcrum Therapeutics, Inc. (FULC) through a
• Adage Capital Partners Cuts Fulcrum Therapeutics Stake to 1.9% — SC 13G/A · Feb 7, 2024
  Adage Capital Partners, L.P. filed an amended SC 13G/A on February 7, 2024, disclosing its ownership in Fulcrum Therapeutics, Inc. As of December 31, 2023, Adag

Risk Profile

Risk Assessment: Of FULC's 22 recent filings, 2 were flagged as high-risk, 14 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Fulcrum Therapeutics, INC.'s most recent 10-Q filing (Oct 29, 2025):

• Revenue: $0
• Net Income: -$54.5M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $47.1M
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Robert J. Gould
• Alex Sapir
• Bryan Stuart
• Dr. S. Brooks Marshall
• Ms. Jennifer L. D. Allison
• James Collins
• James Geraghty
• Abigail P. Johnson

Industry Context

Fulcrum Therapeutics operates in the highly competitive biotechnology sector, focusing on developing small molecules for rare diseases. The industry is characterized by long development cycles, significant capital requirements, and high failure rates in clinical trials. Success hinges on innovation, effective clinical execution, and securing substantial funding for research and development.

Top Tags

financials (5) · 10-Q (4) · pharmaceuticals (3) · biotech (3) · 8-K (2) · Biotechnology (2) · Rare Diseases (2) · Clinical Trials (2) · Net Loss (2) · Cash Burn (2)

Key Numbers

• Commission File Number: 001-38978 — Identifies the company's SEC filing history
• IRS Employer Identification No.: 47-4839948 — Tax identification for the company
• SEC File Number: 001-38978 — Identifies the company's filing with the SEC
• Business Phone: 617-651-8851 — Contact number for the company's principal executive offices
• Net Loss: $54.5M — Increased from a $6.8M net income in the prior year period, primarily due to zero collaboration revenue.
• Collaboration Revenue: $0 — Down from $80.0M in the nine months ended September 30, 2024, indicating a significant loss of income.
• Accumulated Deficit: $573.9M — Increased from $519.4M at December 31, 2024, highlighting sustained unprofitability.
• Cash and Cash Equivalents: $47.1M — Decreased from $58.2M at December 31, 2024, reducing the company's liquidity.
• Marketable Securities: $153.6M — Decreased from $182.8M at December 31, 2024, further impacting available capital.
• Research and Development Expenses: $40.7M — Decreased from $51.7M in the prior year, potentially reflecting cost-cutting or reduced program activity.
• Common Shares Outstanding: 54,118,438 — As of October 22, 2025, indicating potential for dilution if more capital is raised via equity.
• General and Administrative Expenses: $10.5M — for Q2 2025, increased from $7.4M in prior year
• Period End Date: 2025-06-30 — date of the reported financial results
• Reporting Period End Date: 2025-03-31 — Indicates the end of the fiscal quarter for which the report is filed.
• Filing Date: 2025-05-01 — The date the 10-Q was officially submitted to the SEC.

Forward-Looking Statements

• {"claim":"FMR LLC will likely maintain its significant stake in Fulcrum Therapeutics for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"medium"}

Related Companies

SNY

Frequently Asked Questions